RB110 and RB157 antibodies recognize by ELISA specific phosphorylation patterns on CCR5 C-terminal peptides

Recombinant antibodies RB110 and RB157 can be used in ELISA assays to specifically detect human CCR5 phosphorylated at serines 336/337 and at serine 349, respectively

Potent Anti-HIV Chemokine Analogs Direct Post-Endocytic Sorting of CCR5.

G protein-coupled receptors (GPCRs) are desensitized and internalized following activation. They are then subjected to post-endocytic sorting (degradation, slow recycling or fast recycling). The majority of research on post-endocytic sorting has focused on the role of sequence-encoded address structures on receptors. This study focuses on trafficking of CCR5, a GPCR chemokine receptor and the principal entry coreceptor for HIV. Using Chinese Hamster Ovary cells stably expressing CCR5 we show that two different anti-HIV chemokine analogs, PSC-RANTES and 5P14-RANTES, direct receptor trafficking into two distinct subcellular compartments: the trans-Golgi network and the endosome recycling compartment, respectively. Our results indicate that a likely mechanism for ligand-directed sorting of CCR5 involves capacity of the chemokine analogs to elicit the formation of durable complexes of CCR5 and arrestin2 (beta-arrestin-1), with PSC-RANTES eliciting durable association in contrast to 5P14-RANTES, which elicits only transient association

Arrestin recruitment to c-c chemokine receptor 5: potent c-c chemokine ligand 5 analogs reveal differences in dependence on receptor phosphorylation and isoform-specific recruitment bias

C-C chemokine receptor 5 (CCR5) is a chemokine receptor belonging to the G protein-coupled receptor (GPCR) superfamily. An established anti-human immunodeficiency virus drug target, CCR5 is attracting significant additional interest in both cancer and neuroinflammation. Several N-terminally engineered analogs of C-C chemokine ligand 5 (CCL5), a natural ligand of CCR5, are highly potent CCR5 inhibitors. The inhibitory mechanisms of certain analogs relate to modulation of receptor desensitization, but the cellular and molecular mechanisms have not been fully elucidated. Here we made use of a collection of CCR5 phosphorylation mutants and arrestin variants to investigate how CCL5 analogs differ from CCL5 in their capacity to elicit both CCR5 phosphorylation and arrestin recruitment, with reference to the current "core" and "tail" interaction model for arrestin-GPCR interaction. We showed that CCL5 recruits both arrestin 2 and arrestin 3 to CCR5 with recruitment, particularly of arrestin 2, strongly dependent on the arrestin tail interaction. 5P12-RANTES does not elicit receptor phosphorylation or arrestin recruitment. In contrast, PSC-RANTES induces CCR5 hyperphosphorylation, driving enhanced arrestin recruitment with lower dependence on the arrestin tail interaction. 5P14-RANTES induces comparable levels of receptor phosphorylation to CCL5, but arrestin recruitment is absolutely dependent on the arrestin tail interaction, and in one of the cellular backgrounds used, recruitment showed isoform bias toward arrestin 3 versus arrestin 2. No evidence for ligand-specific differences in receptor phosphorylation patterns across the four implicated serine residues was observed. Our results improve understanding of the molecular pharmacology of CCR5 and help further elucidate the inhibitory mechanisms of a group of potent inhibitors. SIGNIFICANCE STATEMENT: C-C chemokine receptor 5 (CCR5) is a key drug target for human immunodeficiency virus, cancer, and inflammation. Highly potent chemokine analog inhibitors act via the modulation of receptor desensitization, a process initiated by the recruitment of arrestin proteins. This study shows that potent C-C chemokine ligand 5 analogs differ from each other and from the parent chemokine in the extent and quality of CCR5-arrestin association that they elicit, providing valuable insights into CCR5 pharmacology and cell biology that will facilitate the development of new medicines targeting this important receptor

Generating Chemokine Analogs with Enhanced Pharmacological Properties Using Phage Display

Phage display technology, which allows extremely rare ligands to be selected from libraries of variants according to user-defined selection criteria, has made a huge impact on the life sciences. In this chapter, we describe phage display methods for the discovery of chemokine analogs with enhanced pharmacological properties. We discuss strategies for chemokine library design and provide a recommended technique for library construction. We also describe cell-based library selection approaches that we have used to discover chemokine analogs, not only receptor antagonists but also variants with unusual effects on receptor signaling and trafficking. By providing a survey of the different phage chemokine projects that we have undertaken, we comment on the parameters most likely to affect success. Finally, we discuss how phage display-derived chemokine analogs with altered pharmacological activity represent valuable tools to better understand chemokine biology, and why certain among them have the potential to be developed as new medicines

Ligand-directed post-endocytic sorting of CCR5 is not dependent on G protein signaling.

<p>CHO CCR5 cells growing on glass coverslips were incubated overnight with Pertussis toxin (100 ng/mL), then washed and stimulated with 100 nM chemokines as indicated in the presence of anti-CCR5 antibody 3A9 (green) at 37°C. Cells were then acid washed (15 min 4°C) to remove cell surface antibody, fixed, permeabilized, and labelled for either the ERC marker Rab11 (5P14-RANTES) or the TGN marker TGN38 (PSC-RANTES) (red). After staining with DAPI nucleic acid stain (blue), cells were analysed by confocal microscopy. Maximum intensity projections are shown, scale bar = 20 μm. Throughout the experiment the ERC and TGN markers (red) remain either in a discrete supranuclear spot (ERC) or at a perinuclear site (ring-shaped staining around the nuclei, TGN). Initially, CCR5 (green) is localized at the cell surface, but after 10 min incubation with either ligand it translocates to the supranuclear spot (visibly colocalizing with the ERC marker used in the cells treated with 5P14-RANTES). After 120 min incubation, CCR5 on cells treated with PSC-RANTES subsequently relocates from the ERC to accumulate in a perinuclear site (ring-shaped staining around the nuclei, visibly colocalizing with the TGN marker), while CCR5 in cells treated with 5P14-RANTES remains colocalized with the ERC marker.</p

Ligand-induced GRK phosphorylation of CCR5.

<p>CHO-CCR5 cells growing on coverslips were treated with the indicated chemokines (100 nM) for the indicated times, then washed, fixed, permeabilized and labeled with a monoclonal antibody specific for CCR5 phosphorylated on Serine 349 (green) and DAPI nucleic acid stain (blue). Maximal intensity projections are shown. Scale bar = 20 μm.</p

Spatial and temporal resolution of arrestin2-CCR5 association.

<p><b>A</b> CHO-CCR5 cells stably transfected with arrestin2-GFP were treated with chemokine analogs (100 nM) as indicated and the redistribution of arrestin2-GFP was followed by live fluorescence microscopy. Images captured prior to (0 min) and after ligand treatment (6 min) are shown. <b>B</b> CHO-CCR5 cells stably transfected with arrestin2-GFP (green), preincubated with rhodamine-labeled anti-CCR5 antibody (red), were washed and then incubated 90 min at 37°C with chemokine analogs (100 nM) prior to image capture. Maximal intensity projections are shown. Scale bar = 20 μm.</p

Antibodies used in this study.

<p>*where possible, stable public identifiers from the Antibody Registry (<a href="http://www.antibodyregistry.org/" target="_blank">www.antibodyregistry.org</a>) are provided; HRP; Horseradish peroxidase.</p><p>Antibodies used in this study.</p

G protein signaling of chemokine analogs on CHO-CCR5 cells.

<p><b>A.</b> G_i/o protein signaling activity of chemokines at the indicated doses was determined by measuring reduction in forskolin-stimulated cAMP levels. Results shown (Relative Light Units, RLU) are the mean of duplicate readings, with error bars indicating the range. <b>B.</b> G protein signaling activity of chemokines (100 nM) was determined by measuring reduction in forskolin-stimulated cAMP levels. Where indicated CHO-CCR5 cells were pre-incubated (100 ng/mL, overnight) with Pertussis toxin (PTX). Results shown (Relative Light Units, RLU) are the mean of duplicate readings, with error bars indicating the range.</p

Ligand-directed post-endocytic sorting of CCR5.

<p><b>A.</b> CHO CCR5 cells growing on coverslips were pre-treated (60 min, 4°C) with 100 nM chemokines and anti-CCR5 antibody 3A9 (green), then washed and incubated at 37°C for the indicated times. Cells were then acid washed to remove cell surface antibody, then fixed, permeabilized, and labeled for the ERC marker Rab11 (red) and DAPI (blue, nuclear staining) prior to analysis by confocal scanning microscopy are shown, scale bar = 20 μm. Throughout the experiment the ERC marker (red) remains in a discrete supranuclear spot that is visble in the center of the nuclei (blue) in the maximum intensity projections. Initially, CCR5 (green) is localized at the cell surface, but after 10 min incubation with either ligand it translocates to colocalize with the ERC marker. After 120 min incubation, CCR5 on cells treated with PSC-RANTES subsequently relocates from the ERC to accumulate in a perinuclear site (ring-shaped staining around the nuclei), while CCR5 in cells treated with 5P14-RANTES remains colocalized with the ERC marker. <b>B.</b> Individual Z-slice images from an identical experiment in which cells incubated with the indicated chemokines for 180 min were also labeled for either the ERC marker, Rab11 or the TGN marker, TGN38 (red). Slices in which the marked compartment is most abundant (through the middle of the nucleus for TGN, just above the nucleus for ERC) were chosen. While in cells treated with PSC-RANTES for 180 min, CCR5 colocalizes with TGN38 and does not colocalize with Rab11, in cells treated with 5P14-RANTES for 180 CCR5 colocalizes with Rab11 and does not colocalize with TGN38 scale bar = 20 μm.</p